Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV)

被引：1
|
作者：
Khasraw, M. [1 ]
Abrey, L. E. [1 ]
Lassman, A. B. [1 ]
Hormigo, A. [1 ]
Nolan, C. [1 ]
Gavrilovic, I. T. [1 ]
Mellinghoff, I. K. [1 ]
Reiner, A. S. [1 ]
DeAngelis, L. M. [1 ]
Omuro, A. M. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.2065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2065
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas
    Eric T. Wong
    Joshua Timmons
    Amy Callahan
    Lauren O’Loughlin
    Bridget Giarusso
    David C. Alsop
    BMC Cancer, 16
  • [22] Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study (vol 28, pg 2051, 2010)
    Perry, James R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (21) : 3543 - 3543
  • [23] Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients
    Silvani, A
    Eoli, M
    Salmaggi, A
    Lamperti, E
    Maccagnano, E
    Broggi, G
    Boiardi, A
    JOURNAL OF NEURO-ONCOLOGY, 2004, 66 (1-2) : 203 - 208
  • [24] Phase II Trial of Cisplatin Plus Temozolomide, in Recurrent and Progressive Malignant Glioma Patients
    Antonio Silvani
    Marica Eoli
    Andrea Salmaggi
    Elena Lamperti
    Elio Maccagnano
    Giovanni Broggi
    Amerigo Boiardi
    Journal of Neuro-Oncology, 2004, 66 : 203 - 208
  • [25] RTOG 0625: A RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB WITH EITHER IRINOTECAN (CPT) OR DOSE-DENSE TEMOZOLOMIDE (TMZ) IN RECURRENT GLIOBLASTOMA (GBM)
    Gilbert, Mark R.
    Wang, Meihua
    Aldape, Kern
    Sorensen, A. Gregory
    Mikkelsen, Tom
    Bokstein, Felix
    Woo, Shaio Y.
    Chmura, Steven J.
    Choucair, Ali K.
    Mehta, Minesh
    NEURO-ONCOLOGY, 2010, 12 : 39 - 39
  • [26] Phase II randomized study of preradiation treatment with temozolomide (TMZ) and bevacizumab (BEV) previous to TMZ plus radiation plus BEV versus the same treatment without BEV therapy in unresectable glioblastoma (GB): GENOM 009
    Balana, C.
    Gallego, O.
    Vieitez, J. M.
    De Las Penas, R.
    Herrero, A.
    Peralta, S.
    Luque, R.
    Gil, M.
    Villa, S.
    Etxaniz, O.
    Carrato, C.
    Sepulveda, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] A phase I trial of low-dose cisplatin and conformal re-irradiation for recurrent malignant glioma
    Fisher, B.
    Lukas, L.
    Bauman, G.
    Watling, C.
    Macdonald, D.
    NEURO-ONCOLOGY, 2006, 8 (04) : 485 - 485
  • [28] SORAFENIB (SO) IN ASSOCIATION WITH LOW-DOSE METRONOMIC TEMOZOLOMIDE (TMZ) IN RECURRENT GLIOBLASTOMA MULTIFORME (GBM): PRELIMINARY RESULTS OF A PHASE II STUDY
    Landi, L.
    Zustovich, F.
    Galli, C.
    Lombardi, G.
    Galli, L.
    Amoroso, D.
    Porta, C.
    Fontana, A.
    Andreuccetti, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 330 - 331
  • [29] THE TEMOZOLOMIDE RESCUE STUDY: A PHASE II TRIAL OF CONTINUOUS (28/28) DOSE-INTENSE TEMOZOLOMIDE AFTER PROGRESSION ON CONVENTIONAL 5/28 DAY TEMOZOLOMIDE IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA
    Mason, Warren
    Perry, James
    Belanger, K.
    Kavan, Petr
    Fulton, D.
    Easaw, Jacob
    Kirby, S.
    Macdonald, David
    Shields, C.
    Pouliot, J-F
    NEURO-ONCOLOGY, 2008, 10 (05) : 833 - 833
  • [30] Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas
    Giuseppe Minniti
    Claudia Scaringi
    Vitaliana De Sanctis
    Gaetano Lanzetta
    Teresa Falco
    Domenica Di Stefano
    Vincenzo esposito
    Riccardo Maurizi Enrici
    Journal of Neuro-Oncology, 2013, 111 : 187 - 194
12345